Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$7.81
-7.1%
$7.66
$6.51
$13.27
$8.90M1.6293,866 shs1,153 shs
Biofrontera Inc. stock logo
BFRI
Biofrontera
$0.61
-0.6%
$0.74
$0.58
$2.22
$5.76M0.37922,965 shs41,996 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.85
+3.6%
$2.90
$1.27
$9.47
$9.15M1.671.29 million shs18,263 shs
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$2.30
-12.5%
$1.61
$1.20
$19.95
$3.23M-0.24608,922 shs168,173 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-2.35%-9.86%+1.18%-8.16%-7.12%
Biofrontera Inc. stock logo
BFRI
Biofrontera
-0.57%-8.63%-16.40%-37.43%-44.02%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
+3.64%-12.31%-14.93%+6.74%-4.36%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-12.55%+22.99%+53.33%+18.56%-87.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
2.7392 of 5 stars
3.55.00.00.03.30.80.0
Biofrontera Inc. stock logo
BFRI
Biofrontera
2.1433 of 5 stars
3.53.00.00.01.40.01.3
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
2.5451 of 5 stars
0.05.00.00.03.63.30.6
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
2.7342 of 5 stars
3.55.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
3.00
Buy$30.00284.32% Upside
Biofrontera Inc. stock logo
BFRI
Biofrontera
3.00
Buy$2.75350.67% Upside
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00
N/AN/AN/A
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
3.00
Buy$10.00334.78% Upside

Current Analyst Ratings Breakdown

Latest EVAX, CYCN, BFRI, and ADXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $2.75
4/2/2025
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$404.10K20.48N/AN/A$1.20 per share6.51
Biofrontera Inc. stock logo
BFRI
Biofrontera
$38.00M0.15N/AN/A$3.16 per share0.19
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.08M4.40N/AN/A$4.62 per share0.62
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$3.34M0.96N/AN/A($5.83) per share-0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$11.76M-$0.34N/AN/A850.30%-112.43%-77.95%6/9/2025 (Estimated)
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$5.26M-$1.16N/AN/AN/A-55.32%-48.35%8/5/2025 (Estimated)
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$22.12M-$0.72N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)

Latest EVAX, CYCN, BFRI, and ADXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/9/2025Q1 2025
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$1.4197N/AN/AN/AN/AN/A
5/27/2025Q1 2025
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A
5/15/2025Q1 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million
4/1/2025Q4 2024
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million
3/4/2025Q4 2024
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A$0.22N/A$0.22N/A$1.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/A
4.59
4.59
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/A
1.53
0.94
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
5.07
5.07
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
7.99
1.00
2.80

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
16.14%
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
11.04%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
15.00%
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.20%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
41.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
301.06 million901,000Not Optionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
709.45 million7.73 millionNo Data
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
303.21 million1.73 millionNo Data
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
601.40 million685,000No Data

Recent News About These Companies

Evaxion A/S ADR
Evaxion to present at World Vaccine Congress

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$7.80 -0.60 (-7.08%)
As of 05/29/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$0.61 0.00 (-0.57%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.59 -0.02 (-3.97%)
As of 05/29/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$2.85 +0.10 (+3.64%)
Closing price 05/29/2025 03:58 PM Eastern
Extended Trading
$2.95 +0.10 (+3.51%)
As of 05/29/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Evaxion Biotech A/S stock logo

Evaxion Biotech A/S NASDAQ:EVAX

$2.30 -0.33 (-12.55%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.35 +0.05 (+1.96%)
As of 05/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.